Skip to content
IRONXPEPTIDES
HCG 10000IU research vial, Iron Peptide Research label
Hormonal & Melanocortin

HCG

Also known as hCG, Chorionic gonadotropin, Choriogonadotropin alfa

A placental glycoprotein hormone that activates the luteinizing hormone/choriogonadotropin receptor. It is approved in reproductive medicine and studied for its roles in pregnancy, gonadal steroid production, and cancer biology.

Approved drug substance

Size

2 options
Catalog no.
G10K
Specification
10000IU*10vials
Per kit
10 vials
PricePricing will be published soon

For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.

Overview

Human chorionic gonadotropin is a heterodimeric glycoprotein made mainly by placental syncytiotrophoblast cells. It shares its alpha subunit with LH, FSH, and TSH, while its beta subunit is closely related to LH-beta but carries an extended, heavily glycosylated C-terminal segment that lengthens its circulating half-life. Urinary and recombinant forms are approved for triggering final oocyte maturation in fertility treatment and for male hypogonadotropic hypogonadism. Researchers also study hCG variants, including hyperglycosylated hCG and the free beta subunit, which are produced during implantation and in some cancers.

Class: Glycoprotein hormone (LH/CG receptor agonist)

Mechanism of action

How the compound acts, as described in the literature.

  1. Binds the LH/choriogonadotropin receptor (LHCGR), a G protein-coupled receptor that signals mainly through Gs and cAMP, mimicking LH with a longer duration of action.

  2. In early pregnancy it maintains the corpus luteum and its progesterone production until the placenta takes over steroid synthesis.

  3. In the testis it stimulates Leydig cells to produce testosterone; in men with suppressed gonadotropins, it maintained intratesticular testosterone in a dose-dependent manner (Coviello 2005).

  4. Variants have distinct reported actions: hyperglycosylated hCG promotes trophoblast invasion, and the free beta subunit is produced by some non-trophoblastic cancers (Cole 2010).

Published research

Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.

Evidence & safety

What the research does not show, and the adverse events and regulatory status it reports.

As an ovulation trigger in antagonist IVF cycles, hCG carried a higher risk of ovarian hyperstimulation syndrome than GnRH-agonist triggering in a Cochrane review. A criteria-based meta-analysis found no evidence that hCG is effective for weight loss, and US labeling states it has not been shown to be effective for obesity. Studies in men, including the intratesticular testosterone trial, were small and short.

Specifications

All sizes, exactly as catalogued.

Catalog no.ProductSpecificationVials per kit
G10KHCG10000IU*10vials10
G5KHCG5000IU*10vials10

For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.

More in Hormonal & Melanocortin